Amgen's $727 Million Trading Day Sees 100th Ranking Amidst Three-Day Decline

On March 26, 2025, Amgen's trading volume reached $727 million, ranking 100th in the day's stock market. Amgen's stock price fell by 0.37%, marking the third consecutive day of decline, with a total decrease of 3.27% over the past three days.

Fresenius has received clearance to target Amgen's Prolia with its biosimilars. This development could potentially impact Amgen's market share and revenue from Prolia, a key drug in its portfolio. Investors are closely monitoring the situation as it may influence Amgen's future financial performance and stock price.